Evofem Biosciences, Inc.
- EVFM ยท OTC
- Pharmaceutical Preparations
- San Diego, CA
- 29 employees
- CIK 0001618835
Updated from SEC filings through
Top things to know
Executives
- Saundra Pelletier Chief Executive Officer 10-K, 2026-03-11
- Ivy Zhang Chief Financial Officer 10-K, 2026-03-11
What leadership is saying
“Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream”
Earnings press release (8-K Ex. 99.1), filed May 18, 2026
Evofem Biosciences, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as EVFM on OTC. Revenue was $20.2M in the fiscal year ending December 31, 2025, +4.2% from the year before. It reported about 29 employees. Saundra Pelletier is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.2M 10-K, 2026-03-11 | $19.4M 10-K, 2026-03-11 | $18.2M 10-K, 2025-03-24 | $16.8M 10-K, 2023-04-27 | $8.2M 10-K, 2023-04-27 |
| Operating income | $3.4M 10-K, 2026-03-11 | -$7.7M 10-K, 2026-03-11 | -$17.8M 10-K, 2025-03-24 | -$84.1M 10-K, 2024-03-27 | -$167M 10-K, 2023-04-27 |
| SG&A | $17.1M 10-K, 2026-03-11 | $20.7M 10-K, 2026-03-11 | $26.6M 10-K, 2025-03-24 | $71.5M 10-K, 2024-03-27 | $138M 10-K, 2023-04-27 |
| Net income | $391K 10-K, 2026-03-11 | -$8.9M 10-K, 2026-03-11 | $53.0M 10-K, 2025-03-24 | -$76.7M 10-K, 2024-03-27 | -$205M 10-K, 2023-04-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Saundra Pelletier | Chief Executive Officer | 10-K, 2026-03-11 |
| Ivy Zhang CFO at Evofem Biosciences | Chief Financial Officer | 10-K, 2026-03-11 |
What Evofem Biosciences, Inc. does
for the Gulf Cooperative Commission (GCC) and MENA, under which Pharma 1 is expected to launch PHEXX in the UAE in 2026.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 132.5 million (as of August 12, 2026) | 10-Q, August 14, 2026 |
|---|---|---|
| Public float | $1.2M (as of June 30, 2025) | 10-K, March 11, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 14, 2026 |
| Latest proxy statement | Meeting October 29, 2025 (filed October 29, 2025) | DEF 14A, October 29, 2025 |
| Auditor | Bpm LLP (Sacramento, California) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-15
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-09-23
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-07-20
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-14
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-05-18
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-30
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-16
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-03-19
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2026-03-11
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Evofem Biosciences, Inc.
- What does Evofem Biosciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "for the Gulf Cooperative Commission (GCC) and MENA, under which Pharma 1 is expected to launch PHEXX in the UAE in 2026."
- What is Evofem Biosciences, Inc.'s revenue?
- $20.2M for the fiscal year ending December 31, 2025, from its 10-K filed March 11, 2026.
- Is Evofem Biosciences, Inc. profitable?
- Evofem Biosciences, Inc. reported net income of $391K for the fiscal year ending December 31, 2025.
- How many employees does Evofem Biosciences, Inc. have?
- About 29 as of February 28, 2026, as stated in its annual report.
- Who is the CEO of Evofem Biosciences, Inc.?
- Saundra Pelletier, Chief Executive Officer, as named in a 10-K filed March 11, 2026.
- Who is the CFO of Evofem Biosciences, Inc.?
- Ivy Zhang, Chief Financial Officer, as named in a 10-K filed March 11, 2026.
- Where is Evofem Biosciences, Inc. headquartered?
- San Diego, CA.
- What is Evofem Biosciences, Inc.'s stock ticker?
- EVFM on OTC.
- What industry is Evofem Biosciences, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Evofem Biosciences, Inc.'s website?
- evofem.com. Investor relations: https://investor.evofem.com/overview/default.aspx.
- When does Evofem Biosciences, Inc. report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Evofem Biosciences, Inc. a public company?
- Yes. Evofem Biosciences, Inc. files with the SEC under CIK 0001618835 and trades as EVFM.
- Who audits Evofem Biosciences, Inc.?
- Bpm LLP, Sacramento, California, as named in its latest annual report (10-K).
- How many shares of Evofem Biosciences, Inc. are outstanding?
- 132.5 million shares as of August 12, 2026, from its 10-Q filed August 14, 2026.
- What is Evofem Biosciences, Inc.'s public float?
- $1.2M as of June 30, 2025, as reported on the cover of its 10-K filed March 11, 2026.
- How many business segments does Evofem Biosciences, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 14, 2026.
- When is Evofem Biosciences, Inc.'s annual shareholder meeting?
- October 29, 2025, per its proxy statement (DEF 14A) filed October 29, 2025.